A step forward for LRRK2 inhibitors in Parkinson's disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35675432.
- Also identified by DOI 10.1126/scitranslmed.abq7374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.
Medical subject headings
- Parkinson Disease